Demographic and disease characteristics clonal hematopoiesis cohort
| Characteristic . | Normal (N = 17) . | Cyclic (N = 13) . | SCN (N = 40) . | SDS (N = 27) . |
|---|---|---|---|---|
| Age, y | ||||
| Mean ± SD | 17.2 ± 10.1 | 24.5 ± 14.1 | 11.6 ± 10.3 | 7.9 ± 5.0 |
| Median (range) | 17 (4-34) | 26 (3-47) | 10 (0.25-45) | 6.3 (2-19) |
| Female sex, n (%) | 8 (47.0) | 4 (30.7) | 23 (57.5) | 11 (37.9) |
| G-CSF treatment, n (%)* | 0 (0) | 10 (100) | 38 (100) | 10 (40) |
| ANC per mm3† | ||||
| Mean ± SD | na | 613 ± 554 | 140 ± 150 | 1080 ± 1070 |
| Median (range) | na | 400 | 90 (0-650) | 770 (0-4490) |
| ELANE mutation, n (%)‡ | na | 9 (100) | 39 (100) | na |
| SBDS mutation, n (%) | na | na | na | 27 (100) |
| Allogenic stem cell transplant, n (%) | na | 1 (7.6%) | 10 (25%) | 1 (3.7) |
| AML or MDS, n (%)§ | na | 0 (0) | 2 (5.0%) | 0 (0) |
| Characteristic . | Normal (N = 17) . | Cyclic (N = 13) . | SCN (N = 40) . | SDS (N = 27) . |
|---|---|---|---|---|
| Age, y | ||||
| Mean ± SD | 17.2 ± 10.1 | 24.5 ± 14.1 | 11.6 ± 10.3 | 7.9 ± 5.0 |
| Median (range) | 17 (4-34) | 26 (3-47) | 10 (0.25-45) | 6.3 (2-19) |
| Female sex, n (%) | 8 (47.0) | 4 (30.7) | 23 (57.5) | 11 (37.9) |
| G-CSF treatment, n (%)* | 0 (0) | 10 (100) | 38 (100) | 10 (40) |
| ANC per mm3† | ||||
| Mean ± SD | na | 613 ± 554 | 140 ± 150 | 1080 ± 1070 |
| Median (range) | na | 400 | 90 (0-650) | 770 (0-4490) |
| ELANE mutation, n (%)‡ | na | 9 (100) | 39 (100) | na |
| SBDS mutation, n (%) | na | na | na | 27 (100) |
| Allogenic stem cell transplant, n (%) | na | 1 (7.6%) | 10 (25%) | 1 (3.7) |
| AML or MDS, n (%)§ | na | 0 (0) | 2 (5.0%) | 0 (0) |
Data not available for 3 patients with cyclic neutropenia, 2 patients with SCN, and 2 patients with SDS.
ANC obtained prior to G-CSF therapy is shown. Data not available for 8 patients with cyclic neutropenia and 3 patients with SCN.
Percentage of patients with germ line heterozygous ELANE or biallelic SBDS mutations is shown. Data not available for 4 patients with cyclic neutropenia and 1 patient with SCN.
Subsequent development of AML or MDS. No patient had MDS or AML at the time of sample analysis.